Health Care

Explore Eli Lilly’s July 2026 market update: analyst upgrades, new Alzheimer’s biomarker data, Canadian eczema approval, and European pricing risks.

Explore how Novo Nordisk’s 19% share surge reflects Wegovy’s success and a bold shift toward diversified biopharma growth.

Phathom Pharmaceuticals tackles GI disease with cutting‑edge therapies, trading at $12.16 on Nasdaq – see its growth potential despite a negative P/E ratio.

IQVIA’s former CFO joins Moderna’s board to boost finance strategy and vaccine pipeline growth, adding deep life‑sciences expertise to the company’s leadership.

GSK’s phase‑III lung‑cancer win with Riz‑Rez and new China partnerships boost its oncology pipeline and share price, while shedding Alector to focus on high‑impact therapies.

BioSyent, Inc. leverages license and regulatory expertise to drive growth in Canada’s specialty pharma sector, offering investors a solid track record and future potential.

Satellos Bioscience’s SAT‑3247 shows breakthrough muscle‑regeneration results in DMD, boosting investor confidence and pricing the stock for a potential game‑changing therapy.

VentriPoint Diagnostics: Calgary‑based company using 3‑D imaging tech to boost heart disease diagnostics, expanding market reach amid R&D challenges.

Ocugen, the biotech pioneer targeting cartilage regeneration and joint health, offers investors a glimpse into clinical‑stage innovation and future market potential.

Michael McDonnell’s move from Biogen to Moderna’s board brings seasoned finance leadership, boosting Moderna’s mRNA pipeline while underscoring Biogen’s talent‑driven biotech influence.